KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Elanco Animal Health (ELAN) Accumulated Depreciation & Amortization (2017 - 2025)

Elanco Animal Health (ELAN) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $952.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 43.81% to $952.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $952.0 million through Dec 2025, up 43.81% year-over-year, with the annual reading at $952.0 million for FY2025, 43.81% up from the prior year.
  • Accumulated Depreciation & Amortization hit $952.0 million in Q4 2025 for Elanco Animal Health, up from $662.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $952.0 million in Q4 2025 to a low of $173.0 million in Q1 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged $502.7 million across 5 years, with a median of $528.0 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 146.34% in 2021 and later dropped 12.87% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $716.0 million in 2021, then dropped by 4.75% to $682.0 million in 2022, then grew by 1.76% to $694.0 million in 2023, then decreased by 4.61% to $662.0 million in 2024, then skyrocketed by 43.81% to $952.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ELAN at $952.0 million in Q4 2025, $662.0 million in Q4 2024, and $694.0 million in Q4 2023.